157 results about "Cardiac disorders" patented technology

The invention discloses an electrocardiogram classification system and method fusing multi-scale self-adaptive attention, and relates to the technical field of electrocardiogram classification.The electrocardiogram classification method comprises the steps that electrocardiogram data are collected through a data collection module, and a structured data set is output; the data preprocessing module is used for carrying out data preprocessing on the structured data set; the window data segmentation module obtains a standardized windowed electrocardiosignal; the feature extraction module takes the standardized windowed electrocardiosignals as input, performs three stages of multi-scale convolution feature extraction, liquid neural network dynamic modeling and self-adaptive attention mechanism enhancement, and outputs diagnosis results of nine types of heart diseases; and the training and optimizing module is used for optimizing the extraction and classification capability of the model on the electrocardiosignal features, so that the technical effects of full-process technical upgrading from data acquisition, preprocessing, feature extraction to model training optimization and high-precision electrocardiogram automatic classification are achieved.

The invention discloses a multi-mode-based flexible wearable heart function monitoring method, system and device, and relates to the technical field of health monitoring, and the method comprises the steps: outputting a multi-mode signal through a flexible patch sensing module when the flexible patch sensing module is arranged in a detection area; wherein the flexible patch sensing module comprises an electrocardio sensor, a pulse wave sensor, a heart sound sensor, a strain sensor and a microfluidic biosensor. According to the invention, high-precision synchronous signal acquisition is realized through flexible patch integrated multi-modal sensing, heart multi-source signal features are adaptively extracted in combination with a multi-scale convolutional neural model, and timing sequence relevance is captured by using a bidirectional long-short-term memory network, so that the accuracy and reliability of heart disease diagnosis are remarkably improved, and the accuracy and reliability of heart disease diagnosis are improved. Meanwhile, non-invasive and continuous monitoring and early pathological screening are supported.

The invention provides a heart electro-mechanical coupling cross-modal time-space-semantic alignment method, which comprises the following steps: acquiring a multi-modal medical data set, and performing spatial registration on the multi-modal medical data set through a dynamic mapping matrix constructed based on a deformable convolutional network to obtain a spatial coupling medical data set; performing time sequence synchronization on the space coupling medical data set based on a double-flow time convolution network to obtain a space-time coupling medical data set; performing cross-modal pathological semantic alignment on the space-time coupling medical data set through a prototype semantic contrast learning framework to obtain a space-time-semantic alignment data set; and data mining is performed on the space-time-semantic alignment data set based on a triple sparse cross attention mechanism to obtain fusion features, and the fusion features are used for quantifying the importance of each data in the space-time-semantic alignment data set. By adopting the method, cross-modal space-time consistency alignment and semantic calibration can be realized, so that the heart disease pathology association mining capability and the intelligent diagnosis accuracy are improved.

The invention relates to a three-dimensional electrocardio scatter diagram analysis method and device based on heart rate variability and a medium, and relates to the technical field of biomedical signal processing. According to the method, the heart rate data of the user can be mapped into the three-dimensional points in the three-dimensional coordinate system after being preprocessed, the coordinate axes of the three-dimensional coordinate system are the time domain index, the frequency domain index and the nonlinear index, the heart rate change is displayed from three dimensions, compared with a traditional two-dimensional scatter diagram, the heart rate change characteristics can be more comprehensively and stereoscopically displayed, and the user experience is improved. According to the method, more potential heart disease related information is captured, heart rate data features are deeply excavated by constructing a three-dimensional electrocardiogram scatter diagram containing more heart rate change information, heart rate scatter indexes are quantified, and risk levels of heart diseases such as arrhythmia and atrial fibrillation are scientifically and accurately evaluated according to the scatter indexes. And the accuracy and reliability of heart disease risk assessment are improved.

The invention provides a hierarchical multi-modal heart data completion method based on double knowledge guidance, which comprises the following steps: S1, extracting complete multi-modal joint features from complete multi-modal data through a teacher network, and carrying out cross-sample comparative learning and dynamic feature fusion on missing modal data through a student network to obtain a multi-modal data fusion model; generating completion features containing individual specific information; s2, based on the completion features, constructing a category prototype vector of the heart disease subtype, and generating semantic constraints representing disease subtype rules through prototype perception comparison distillation and moving average evolutionary strategies; s3, the complementation features and the semantic constraints are combined, network parameters and prototype vectors are optimized through back propagation iteration, complementation data are generated, and the complementation data comprise individual electrophysiological features and pathological subtype marks. By adopting the method, the individual specificity and the pathological evolution rule can be considered, and the reconstruction data can be ensured to meet the accurate heart disease diagnosis requirement at the same time.

The invention provides an application of human source circular RNA hsacirc0083796 in preparation of a diagnostic reagent or a medicine for diagnosing and / or treating aortic dissection. The invention also provides a kit for diagnosing the aortic dissection. The invention also provides a pharmaceutical composition for treating aortic dissection. According to the application of the human source circular RNA in preparation of heart disease related products, the related heart disease related circular RNA (circled-Frizzled class receptor 3, hsacirc0083796) is one of circular RNAs with the highest expression quantity in the blood of aortic dissection patients and has high conservative property, the function of the circular RNA is closely related to heart diseases, and the circular RNA has a good application prospect in preparation of heart disease related products. The method has great significance in diagnosis and treatment of heart diseases. Meanwhile, due to the stable and specific properties of the circular RNA, compared with other types of markers, the circular RNA has larger abundance in body fluid of a patient and more obvious change, so that the circular RNA has the potential of becoming a novel diagnostic marker.

The invention discloses a signal acquisition system of a self-adaptive film electrode patch for heart diseases, and relates to the technical field of medical instruments, the signal acquisition system comprises a flexible substrate, a nano electrode wire, an electrode patch and a circuit module; a bonding layer is arranged on the bottom surface of the flexible substrate, an anti-allergic medicine is distributed in the bonding layer, and the flexible substrate is used for being attached to the skin surface through the bonding layer; the plurality of nano electrode wires are distributed on the bonding layer of the flexible substrate, one ends of the plurality of nano electrode wires are respectively arranged at the detection points, the other ends of the plurality of electrode wires are connected with the circuit module, and the circuit module is used for outputting electric signals collected by the electrode paste; the electrode patch comprises a flexible conductive base layer and a contact layer, a printed circuit is arranged on one side of the flexible conductive base layer, the contact layer is attached to the printed circuit, the other side of the flexible conductive base layer is used for being bonded to a flexible substrate and located at a detection point, and the flexible conductive base layer is conducted with the nano electrode wire; the collection system is simple to operate, and solves the problems that an existing lead wire is easy to wind, the surgical field is affected, and skin allergy is caused by patch. The method has high use value and popularization value.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has a particular cardiac condition, such as a cardiac arrhythmia, myocardial ischemia and / or myocardial infarction, or the like. The machine learning model generates classified feature data that are indicative of the presence and / or likelihood of a particular cardiac condition.

The invention relates to the technical field of biological medicines, in particular to application of a monoclonal antibody in medicines for treating heart diseases related to Alzheimer's disease. According to the application disclosed by the invention, the application range of the lencanamazumab is expanded to prevention and treatment of AD-accompanied heart failure and pathological myocardial remodeling, and a new drug strategy is provided for treatment of patients with AD-associated heart failure or pathological myocardial remodeling.

The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-4784 with SEQ ID NO: 6, or a member of the miR-4784 family, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.

Methods and kits for treating and / or preventing a cardiac disorder are disclosed. The methods can include administering an indole metabolite to a subject. The methods can also include administering a glycopeptide antibiotic to the subject.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

Disclosed herein are methods and compositions for the detection of biomarkers for cardiac diseases. Disclosed herein are sample collection devices comprising detection devices for heart failure. Disclosed herein are methods of detecting, monitoring, preventing, or treating heart failure.

The present invention provides use of a drug targeting the γ-aminobutyric acid transmitter system in the treatment of cardiac diseases. Specifically, the present invention provides use of a drug targeting the γ-aminobutyric acid transmitter system (GABA-TS) in the preparation of a medicament for treating or preventing cardiac diseases. Specifically, the present invention identifies the endogenous γ-aminobutyric acid transmitter system and the regulatory functions contained in atrioventricular node pacemaker cells, providing a novel intervention strategy for arrhythmias.

The invention discloses a medicine for treating the heart of a human body, and particularly relates to the field of medicines, the medicine is prepared from the following components in percentage by mass: 13.8% of radix salviae miltiorrhizae, 4.1% of allium macrostemon, 8.3% of semen trichosanthis, 2% of polygala tenuifolia, 8.3% of radix ophiopogonis, 2% of sandalwood, 6.9% of pericarpium citri reticulatae viride, 13.8% of lily, 8.3% of semen boitae, 10.4% of poria cocos, 8.3% of oriental cherry powder and 13.8% of earthworm, and the sum of the mass percentages of the components is 100%. According to the medicine for treating the heart of the human body, traditional Chinese medicine decoction pieces such as salvia miltiorrhiza, allium macrostemon, snakegourd seeds, polygala tenuifolia, radix ophiopogonis, sandalwood, pericarpium citri reticulatae viride, lily, platycladi seeds, poria cocos, oriental cherry powder and lumbricus are crushed and proportioned according to corresponding formula proportions and processes, so that the medicine plays the maximum effects of all the decoction pieces, is easier to take and absorb, and can be taken for a long time after being taken. The traditional Chinese medicine composition has obvious treatment effects on cardiac insufficiency, dyspnea, weakness, fatigue, angina pectoris, palpitation, palpitation and other problems caused by heart problems of heart disease patients, and can effectively treat coronary heart disease, myocardial ischemia, arrhythmia and other heart diseases.

The present application relates to a kind of cardiac magnetic resonance longitudinal relaxation time measurement method, medium and equipment.The measurement method includes the following steps: S1 uses MOLLI sequence respectively before and after scanning contrast;Specifically, in the before and after scanning contrast, by setting different initial inversion time TI, setting 3 groups of LL experiment LL1, LL2, LL3 triggered by continuous ECG, enough relaxation curve sampling points are obtained after fusion;And data is collected at the end of diastole of cardiac cycle, and 1 image is obtained per heartbeat;S2 image processing.This measurement method can realize single-pixel high-resolution T1 mapping under the breath holding of selection data acquisition and multi-LL experiment data fusion, give consideration to high accuracy, high resolution and high efficiency, and have good compatibility and practicality, provide new scheme for early diagnosis of heart disease, lesion quantification and prognosis evaluation, have wide clinical application prospect.

The invention provides application of ML324 in preparation of drugs for treating and / or preventing heart diseases. The invention shows that the ML324 can prevent and / or treat heart diseases related to myocardial cell death, obviously inhibit activity decline of myocardial cells induced by a cell death inducer Erastin and H2O2, and improve the cell survival rate; generation of active oxygen in cells is reduced, and death modes such as myocardial cell apoptosis are reduced; the compound can be used for preventing, treating and improving heart function damage, myocardial fibrosis and heart organic damage caused by heart diseases, has a good application prospect in the aspect of developing medicines for resisting the heart diseases, and provides a new medicine research and development direction for preventing, treating and improving the heart diseases.

The embodiment of the invention discloses a heart disease prediction model generation method. The method may include a step of acquiring a plurality of electrocardiogram data and a step of generating a model for predicting a heart disease based on the plurality of electrocardiogram data.

The application belongs to the technical field of model prediction, and relates to an abnormality identification method applied to electrocardiograms and related equipment.The method comprises the following steps: performing a first vector conversion operation on historical electrocardiogram data according to an encoding model to obtain a historical time sequence embedding vector; constructing an initial text prototype and calculating an initial text embedding vector of the initial text prototype according to a contrast learning function and the historical time sequence embedding vector; constructing a model loss function according to the historical time sequence embedding vector and the initial text embedding vector; performing a model training operation on the text prototype according to the model loss function to obtain a target text prototype; receiving electrocardiogram data to be analyzed sent by a user terminal; performing a second vector conversion operation on the electrocardiogram data to be analyzed according to a loss encoding model to obtain a time sequence embedding vector to be analyzed; inputting the time sequence embedding vector to be analyzed into the target text prototype to perform an abnormality identification operation and obtaining an abnormality identification result.The application can greatly improve the prediction accuracy of heart diseases.

The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described.

The invention provides a 3D culture method for promoting stem cells to be differentiated into cardiac lineage cells. According to the method, four-stage time sequence induction is adopted, wherein in the stage I, BMP4, Activin A and bFGF are used for efficiently inducing the cells into mesoderm in an insulin-free culture medium; in the stage II, DKK1 is used for inhibiting WNT signals to lock the heart pedigree, and VEGF165 is added in the early stage to start cardiac endothelial differentiation; in the stage III, metabolic support is provided for an insulin-containing culture medium, and bilineage maturation is deepened; in the IV stage, bFGF is added to support long-term survival and function maintenance of the cells, and the whole process is carried out in a 3D embryoid body. According to the invention, the cheap RPMI1640 basal culture medium is used for replacing an expensive commercial culture medium, the high-purity heart micro-tissue which can spontaneously beat and contains cardiac muscle and cardiac endothelial cells can be obtained within about 10 days, and an economical and efficient cell source is provided for heart disease research, drug screening and regenerative medicine.

Disclosed herein, in some aspects, are systems and methods for detecting, monitoring, and managing a cardiac health status for a subject using ECG data. In some embodiments, the system receives health parameter measurements from one or more devices that are then used by a cardiac health tool (CHT) to determine a cardiac health status. Exemplary health parameter measurements include electrocardiogram (ECG) data from an ECG device and / or weight (from a weight scale for example). As described herein, in some embodiments, determining the cardiac health status includes a) detecting a cardiac condition in the subject, b) predicting a risk of a subject developing a cardiac condition (“cardiac condition risk”), and / or c) temporal monitoring of a cardiac health status for a subject. In some embodiments, the cardiac health tool is configured to determine the efficacy of a treatment or therapy applied to reduce the severity and / or risk of a cardiac condition.

The present invention relates the use of an anti-inflammatory agent for inhibiting and / or preventing damage of a peripheral ganglion in a subject, particularly in a subject suffering from a cardiac disease. The present invention also relates to the use of an anti-inflammatory agent for preserving cardiac innervation in a subject suffering from cardiac disease. Further, the present invention relates to method for identifying a subject being at risk of damage of a peripheral ganglion, comprising determining in said subject at least one parameter associated with a risk of damage ganglion damage, wherein the parameter may be a ganglion-specific biomarker. Furthermore, the invention relates to the use of a modulator of at least one of said ganglion-specific biomarkers for preventing damage of a peripheral ganglion in a subject.

The present disclosure provides beating explanted donor hearts from swine, methods of making thereof, and methods of using thereof. The present disclosure further provides methods of treating a disease (e.g., a heart disease) in a human subject in need thereof comprising transplanting of a beating explanted donor heart from swine. The present disclosure also provides medical instruments suitable for transplanting a beating explanted donor heart from swine.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The invention provides an application and a method of GSH in promoting mature differentiation of hiPSC-CMs, and the method is characterized in that in the process of directionally differentiating the hiPSC-CMs into the hiPSC-CMs, an effective dose of GSH is added into a differential medium, and the optimal concentration is 20-100 [mu] M. According to the invention, through simple and economical exogenous supplement of GSH, maturation of hiPSC-CMs is systematically promoted from multiple dimensions, including enhancement of intracellular anti-oxidation defense capability; energy metabolism is promoted to be converted from glycolysis to oxidative phosphorylation; up-regulating expression of cardiac muscle cell specific structural protein and calcium ion channel related genes; mitochondrial biological generation and functions are promoted; and the cell morphological structure is induced to develop to a mature phenotype. The method is simple and convenient to operate and high in biocompatibility, the hiPSC-CMs with mature functions can be stably obtained, and a high-quality cell source is provided for application of the hiPSC-CMs in the fields of heart disease modeling, drug cardiotoxicity screening and the like.

The application discloses a heart disease detection system based on an electrocardiosignal, and the system comprises an acquisition module configured to acquire an electrocardiosignal to be detected, a preprocessing module configured to perform a preprocessing operation on the electrocardiosignal to be detected, extract a wave band vector, a beat vector and a window segment vector from the preprocessed signal, convert the wave band vector into a wave band input matrix, and convert the beat vector into a beat input matrix, and a detection module configured to input the preprocessed electrocardiosignal into a trained heart disease detection model and output a heart disease detection result. The application can improve the accuracy of heart disease detection.

Disclosed are screening methods and compositions for identifying compounds that correct pathological electrophysiological phenotypes associated with sodium channel-related cardiac diseases, such as SCN5A- related cardiac diseases, that are difficult to identify with conventional preclinical models. The in vivo zebrafish models and screening methods disclosed facilitate the study and discovery of therapeutic compounds to treat sodium channel-related cardiac diseases, e.g., by increasing sodium channel function at the membrane.